AI Article Synopsis
- A 71-year-old man with symptoms like headaches and vision problems was diagnosed with a pituitary fossa lesion and thyroid cancer that had metastasized to his brain.
- Imaging tests revealed a significant tumor affecting multiple areas, and a biopsy confirmed the presence of metastatic papillary adenocarcinoma.
- The study includes a literature review of similar cases to understand the clinical features, treatment, and outcomes related to thyroid cancer spreading to the pituitary gland.
Article Abstract
Background: A 71-year-old man presented with a history of headaches, blurred vision, diplopia, and right-sided ptosis. Magnetic resonance imaging (MRI) of the head revealed a 2.5 cm pituitary fossa lesion distorting the optic chiasm, with cavernous sinus invasion and frontal, temporal, and parieto-occipital lesions. Computed tomography (CT) found a retrosternal thyroid goiter. Biopsy of the occipital lobe lesion revealed metastatic papillary adenocarcinoma. Ultrasound-guided fine needle aspiration of the goiter and abnormal lymph nodes revealed Thy5. The patient underwent endoscopic transsphenoidal resection of the pituitary tumor, confirming papillary carcinoma of the thyroid. We sought to understand the clinico-radiological and histopathological features, treatment strategies, and outcomes of patients with thyroid cancer metastasis to the pituitary fossa.
Materials And Methods: A date- and language-unrestricted literature search was performed across the MEDLINE, Embase, and Scopus databases using keywords relating to metastasis, the pituitary and thyroid glands, and the brain. Citations reporting patients with thyroid metastasis to the pituitary fossa were included. A proforma was used to extract and store data from the included citations.
Results: After deduplication, 2,833 citations were screened for eligibility, and 49 citations were included in the analysis.
Conclusion: We present a rare case illustration and comprehensive literature review of patients with thyroid cancer metastasis to the pituitary fossa.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5414/NP301649 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Utility of F18-FDG PET/CT in the Evaluation of Pituitary Uptake.
World J Nucl Med
December 2024
Department of Nuclear Medicine, Christian Medical College and Hospital, Vellore, Tamil Nadu, India.
Pituitary adenoma is the most common disease that affects the gland and may be classified as functional/nonsecretory tumors. Inflammatory/infective causes may also affect the pituitary gland. The 18F-fluorodeoxyglucose positron emission tomography/computed tomography (F18-FDG PET/CT) may have an incremental value in assessing these lesions and in determining their clinical significance.
View Article and Find Full Text PDFArticle Synopsis
- A 71-year-old man with symptoms like headaches and vision problems was diagnosed with a pituitary fossa lesion and thyroid cancer that had metastasized to his brain.
- Imaging tests revealed a significant tumor affecting multiple areas, and a biopsy confirmed the presence of metastatic papillary adenocarcinoma.
- The study includes a literature review of similar cases to understand the clinical features, treatment, and outcomes related to thyroid cancer spreading to the pituitary gland.
Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53.
Endocr Pathol
December 2024
Department of Pathology, University of California San Francisco (UCSF), 505 Parnassus Avenue, Room M-559, San Francisco, CA, 94143, USA.
High-grade or grade 3 epithelial neuroendocrine neoplasms (G3 NEN) are now divided into grade 3 well-differentiated neuroendocrine tumor (G3 NET) and neuroendocrine carcinoma (NEC), both defined by Ki-67 > 20% and/or > 20 mitoses per 2 mm. NET and NEC are thought to be distinct tumors with different genetic profiles: NEC classically harbors co-alteration of TP53 and RB1, whereas NET genetics are site-dependent with frequent alterations in MEN1, ATRX, DAXX, and TSC1/2 in pancreatic NETs. Progression from NET to NEC is considered rare and is not well described.
View Article and Find Full Text PDFSolitary pituitary metastasis from breast cancer masquerading as a pituitary macroadenoma: a report of 2 rare cases.
Gland Surg
October 2024
Laboratory of Cellular and Molecular Biology, School of Basic Medicine, Central South University, Changsha, China.
Background: Breast cancer is one of the most common malignant tumors, occurring in the mammary glands, which often metastasizes to bones, lungs, and liver. However, pituitary metastasis (PM) originating from breast cancer is a rare phenomenon that can easily be mistaken for benign pituitary macroadenoma.
Case Description: This report details two cases of middle-aged and elderly Chinese women who presented with serious neurological symptoms, each with a history of breast malignancy.
Clinical features of pituitary carcinoma: analysis based on a case report and literature review.
Front Endocrinol (Lausanne)
November 2024
Department of Neurosurgery, The General Hospital of Western Theater Command, Chengdu, China.
Introduction: Pituitary carcinoma (PC) is an extremely rare tumor of the adenohypophysis, which manifests as craniospinal dissemination and/or systemic metastasis. The diagnosis of PC is particularly difficult, as the clinical diagnosis only can be made after the metastasis is found. Owing to the complex diagnostic process and less effective treatments, the clinical prognosis of PC is usually very poor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!